Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

e III endpoint is substantially smaller than the 33% increase seen in Phase II.
  • No toxicity issues have been identified.
  • No safety issues have been identified.
  • Clear unmet medical need.
  • FDA granted Multikine Orphan Drug status in the USA.

  • Our clinical success would be huge since Multikine would be on course to become the recommended first-line treatment for head and neck cancer. From there, we could hopefully prove that Multikine is likely to work against other solid tumors as well.

    Our ultimate goal in development is to provide patients and physicians with a new and better way of fighting cancer. We believe that the key to doing so lies in our immune system. Dendreon's prostate cancer vaccine recently established that this is possible. Their success is even more impressive because they focused on late-stage cancer patients. We believe that Multikine should have an even greater chance of success because we focus on patients not yet treated for their cancer. Their immune system is still intact, except in the area of the tumor, and their lymphatics have not yet been cut, meaning that they can still deliver immune cells from the local lymph nodes to the tumor.

    From here on there is only one thing to do. We will launch the Phase III study as quickly as possible. Success would be phenomenal, and we anticipate that it should enable rapid approval around the world.

    We thank you for your continued support.

    Sincerely,

    Geert Kersten

    Chief Executive Officer

    When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected.
    '/>"/>

    SOURCE CEL-SCI Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. CEL-SCI to Present at the Noble Financial Conference
    2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
    3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
    4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    5. CEL-SCI Takes Delivery of New Manufacturing Facility
    6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
    7. CEL-SCI Corporation Releases Letter to Shareholders
    8. CEL-SCI Corporation Announces 2008 Financial Results
    9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
    10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
    11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... 10, 2014 Unraveling life’s mysteries can ... The Archer Family purchased a DNA test ... ended up with a lifetime of memories, sharing, and ... family members’ DNA genuinely brought the family closer together. ... deeper into genetic history and prior to taking the ...
    (Date:7/10/2014)... Ind. , July 10, 2014 /PRNewswire/ ... its use of capnography for respiratory monitoring ... group of healthcare leaders in embracing state-of-the-art ... how effectively patients are breathing and can ... occurs. By measuring the amount of carbon ...
    (Date:7/10/2014)...   Ceres, Inc . (Nasdaq: CERE ... financial results for the three months ended May 31, ... Ceres reported that the company and its customers ... season in Brazil, which concluded in June, despite dry ... areas for part of the growing season. Yields of ...
    (Date:7/10/2014)... the basis of psychiatric disorders has been extremely challenging ... risk but are insufficient to cause disease. Now investigators ... Press journal Cell Stem Cell describe a ... risks interact with other risk factors or environmental exposures ... research pinpoints a genetic variant that may predispose individuals ...
    Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2
    ... Madison, Wis. - CDW Corp. , a $6 ... Hills, Ill., has agreed to acquire the stock of Madison-based ... cash. , ,The acquisition, which has been approved by ... the end of October, subject to regulatory approvals and approval ...
    ... Madison, Wis. - Not everyone is a fan ... most up-to-date technology - fiber to the premises. , ... the pack with trailing-edge technology is pervasive, but ... a different calculation. , ,TDS has introduced its Symmetrical ...
    ... Stem Cell Bank has announced it will receive human ... , giving it 13 of the 21 stem cell lines ... of the WiCell Research Institute , which houses the ... eventually will have all 21 federally approved lines. , ,"We're ...
    Cached Biology Technology:Berbee believes acquisition by CDW will make it a national IT player 2Berbee believes acquisition by CDW will make it a national IT player 3TDS believes faster DSL service will suit small businesses 2Nation's only stem cell bank will receive UC-San Francisco cell line 2
    (Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
    (Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
    (Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
    Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
    ... a human hair to deliver drugs to cells or assist ... of a science fiction movie, but these scenarios may be ... Carbon nanotubes, cylindrically shaped carbon molecules with a diameter of ... of fields, such as biomedical engineering and medical chemistry. ...
    ... The National Institutes of Health (NIH) has awarded ... University and PATH, a Seattle-based nonprofit organization, to advance ... using patches containing tiny microneedles that dissolve into the ... address key technical issues and advance the microneedle patch ...
    ... Elsevier ( www.elsevier.com ) , a world-leading ... and services, today announced the launch of SciVerse ... platform that will empower the scientific community to ... search and discovery process through its marketplace and ...
    Cached Biology News:Nanotechnology: A dead end for plant cells? 2NIH awards $10 million to advance microneedle patch for flu vaccination 2NIH awards $10 million to advance microneedle patch for flu vaccination 3NIH awards $10 million to advance microneedle patch for flu vaccination 4Elsevier launches SciVerse Applications beta 2Elsevier launches SciVerse Applications beta 3
    Based on Silica membrane matrix beads. The kit is designed for the purification of DNA (20 bp - 100 bp) from TAE/TBE agarose gels. Run time is approximately 45 minutes....
    ... DNA and Gel Band Purification Kit, 100. For ... and DNA fragments (0.1-10 kb) from solution and ... DNA fragments from solution in as little as ... in 15 min.Prepacked glass fiber matrix columns provide ...
    These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
    Newborn Bovine Serum Heat-Inactivated...
    Biology Products: